An Australian stem cell and regenerative medicine company

Cynata Therapeutics

Mesenchymal stem cells (MSCs) have huge therapeutic potential for numerous unmet medical needs.

This has already been demonstrated and is widely documented.

Cynata’s unique Cymerus™ technology addresses many of the complexities and challenges of manufacturing these cells at commercial scale.

Using leading edge science from the world’s pre-eminent stem cell center we have a starting material with unlimited expansion potential, which means that we and our commercial partners can source all the cells we will ever need from a single blood donation.

This in turn means we can manufacture robust and consistent MSCs in an economically viable process – all under Good Manufacturing Practice (GMP) requirements.

Learn more about Cymerus™ here, and how Cynata is set to accelerate the commercialization of MSC therapies worldwide.

About our technology

About our technology

Watch our animation on Cynata’s Cymerus™ unique stem cell technology